117018-99-2

Basic information

• Product Name: 1-(2-bromoethyl)pyrrolidin-2-one
• Synonyms: 1-(2-bromoethyl)pyrrolidin-2-one;2-pyrrolidinone, 1-(2-bromoethyl)-;1-(2-bromoethyl)-2-pyrrolidinone(SALTDATA: FREE);1-(2-bromoethyl)-2-pyrrolidinone
• CAS NO: 117018-99-2
• Molecular Formula: C₆H₁₀BrNO
• Molecular Weight: 192.0537
• Mol File: 117018-99-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 278.6 °C at 760 mmHg
• Flash Point: 122.3 °C
• Appearance: /
• Density: 1.511 g/cm³
• Vapor Pressure: 0.00423mmHg at 25°C
• Refractive Index: 1.529
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.67±0.20(Predicted)
• CAS DataBase Reference: 1-(2-bromoethyl)pyrrolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-bromoethyl)pyrrolidin-2-one(117018-99-2)
• EPA Substance Registry System: 1-(2-bromoethyl)pyrrolidin-2-one(117018-99-2)

Safety Data

• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 117018-99-2(Hazardous Substances Data)

Usage

General Description

1-(2-bromoethyl)pyrrolidin-2-one, also known as 2-Bromomethyl-2-pyrrolidinone, is a chemical compound with the molecular formula C6H9BrNO. It is a heterocyclic compound containing a five-membered ring with a bromoethyl substituent. 1-(2-bromoethyl)pyrrolidin-2-one is commonly used in organic synthesis as a versatile building block for the preparation of various pharmaceuticals and agrochemicals. It can also act as a precursor for the synthesis of other compounds such as chiral auxiliary agents and ligands for asymmetric catalysis. Additionally, 1-(2-bromoethyl)pyrrolidin-2-one has potential applications in the development of new materials and chemical processes due to its unique structure and reactivity. However, it is important to handle this compound with caution as it is a potentially hazardous chemical.

InChI:InChI=1/C6H10BrNO/c7-3-5-8-4-1-2-6(8)9/h1-5H2

Upstream product

• 3445-11-2 1-(2-hydroxyethyl)-2-pyrrolidinone 
• 616-45-5 2-pyrrolidinon 
• 106-93-4 ethylene dibromide 

Downstream Products

• 855308-11-1 Rh(5,10,15,20-tetratolylporphyrinato)(β-N-pyrrolidonylethyl) 
• 1441746-91-3 4-(4-chloro-2-methyl-phenyl)-5-(5-chloro-2-methyl-phenyl)-3-isopropyl-2-[2-(2-oxo-pyrrolidin-1-yl)-ethyl]-4,5-dihydro-2H-pyrrolo[3,4-c]pyrazol-6-one 
• 117018-95-8 N-(β-Thiosulfoethyl)-2-pyrrolidone sodium salt 

Relevant articles and documents

PH-responsive surface activity and solubilization with novel pyrrolidone-based gemini surfactants

A new series of pH-responsive Gemini surfactants with 2-pyrrolidone head groups, N,N′-dialkyl-N,N′-di(ethyl-2-pyrrolidone)ethylenediamine (Di-CnP, where n = 6, 8 10, 12), were synthesized and characterized by 1H NMR, 13C NMR, ESI-MS, and elemental analysis. The surface activity and micellization behavior at acidic, neutral, and basic conditions were characterized by equilibrium surface tension and fluorescence techniques. It was found that the surface activity of Di-CnP depends on the pH of aqueous solutions due to the protonation state of surfactant molecules when pH was varied. The new compounds have lower cmc and γcmc in comparison with that of m-2-m type conventional cationic Gemini surfactants and gluconamide-type nonionic Gemini surfactants. Fluorescence data confirm that micelles are formed when the concentration is above the cmc. Since micellization is of fundamental importance in surfactant applications such as solubilization, microemulsion, and related technologies, the significant difference in cmc at different pH of this new Gemini surfactant is employed to solubilize cyclohexane. The preliminary result indeed shows that the solubilization capacity of Di-CnP can be tuned by pH.

BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES

The invention provides bioactive compounds for the treatment of various malconditions such as cancer and neurodegenerative diseases including Alzheimer's disease. The chemical compounds as disclosed herein are found to show bioactivity in bioassays related to these conditions. Pharmaceutical compositions, combinations and methods of synthesis are provided, as are methods of using the compound, compositions and combinations in the treatment of the diseases.